Indaptus Therapeutics Inc. (INDP)
INDP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | INDP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001857044 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "As a result, the conditions that previously raised substantial doubt about the Company's ability to continue as a going concern have been resolved." | 10-Q 2026-11-13 |
| Cash and burn | $7.6M cash; operating cash flow -$3.7M a quarter. | Report 2026-06-30 |
| Shares outstanding | 153,602,583 (2026-11-13); 1,751,163 a year earlier; 8,401,047 three years earlier. 3y figure adjusted for splits (1-for-28 overall). | Cover page 2026-11-13 |
| Reverse splits, 3 years | 1; latest 1-for-28 on 2025-06-27 | Source 2025-06-27 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-09-04 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Haskell & White LLP, Irvine, California, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$1.8M | -$1.9M | $7.6M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$2.5M | -$7.0M | $1.5M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2025 2025-12-31 | Not filed | -$8.1M | -$3.2M | $8.5M | No debt tags | Needs four quarters | 10-K 2026-03-17 |
| Q3 2025 2025-09-30 | Not filed | -$3.0M | -$2.6M | $5.8M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$5.2M | -$4.0M | $6.2M | $12.2M | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$4.5M | -$5.0M | $3.9M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2024 2024-12-31 | Not filed | -$4.1M | -$3.4M | $5.8M | No debt tags | Needs four quarters | 10-K 2026-03-17 |
| Q3 2024 2024-09-30 | Not filed | -$3.1M | -$2.5M | $7.4M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-04 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEF 14A | 2026-07-16 |
Source: SEC EDGAR submissions feed, 345 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.5% |
| 1 month | +32.6% |
| 3 months | +199.1% |
| Year to date | +8.9% |
| 1 year | +7.1% |
| From 52-week high | -33.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CBIO | Crescent Biopharma Inc. | $13.50 | -4.59% | $525.1M |
| ZVRA | Zevra Therapeutics Inc. | $9.25 | +1.87% | $550.4M |
| GYRE | Gyre Therapeutics Inc. | $4.39 | +1.86% | $506.3M |
| EVO | Evotec SE | $1.56 | -1.27% | $555.0M |
| HELP | Helus Pharma Inc. | $7.67 | -13.53% | $560.4M |
| WVE | Wave Life Sciences Inc. | $2.87 | -8.31% | $566.0M |
| ACRS | Aclaris Therapeutics Inc. | $3.60 | -8.04% | $571.8M |
| MNPR | Monopar Therapeutics Inc. | $71.97 | -0.04% | $487.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier